Crinetics Pharmaceuticals, INC

Vertex Pharmaceuticals Incorporated has successfully completed its acquisition of Crinetics Pharmaceuticals, Inc. for $85.00 per share in cash.

Crinetics Pharmaceuticals announced shareholder approval for the merger with Vertex Pharmaceuticals, with the closing anticipated around September 1, 2026.

Crinetics Pharmaceuticals provides supplemental disclosures to its proxy statement to address shareholder concerns and litigation related to its proposed merger with Vertex Pharmaceuticals.

Crinetics Pharmaceuticals announces the expiration of the HSR Act waiting period for its acquisition by Vertex Pharmaceuticals, moving closer to deal closure.

Crinetics Pharmaceuticals announced a definitive agreement to be acquired by Vertex Pharmaceuticals for approximately $10.0 billion, alongside reporting strong second-quarter 2026 financial results driven by PALSONIFY sales.

Crinetics Pharmaceuticals announces a definitive merger agreement with Vertex Pharmaceuticals, including non-compete agreements with key employees.

Crinetics Pharmaceuticals reports strong Q1 2026 results driven by PALSONIFY commercialization, with significant revenue growth and increased R&D investment.

Crinetics Pharmaceuticals reports FDA approval for PALSONIFY in acromegaly, significant R&D pipeline progress, and increased operating losses in its Q3 2025 filing.

Crinetics Pharmaceuticals reports increased losses driven by accelerated R&D and commercialization efforts, while advancing its lead drug candidates Paltusotine and Atumelnant with positive clinical and regulatory updates.

Crinetics Pharmaceuticals announces its Q1 2025 financial results, showcasing ongoing clinical trials and strategic advancements in its endocrine disease and tumor therapeutics pipeline.

Crinetics Pharmaceuticals reported its Q3 2024 financial results, highlighting progress in clinical trials and a recent NDA submission for paltusotine.

Crinetics Pharmaceuticals reported its financial results for the second quarter of 2024, highlighting progress in its clinical programs and financial position.

Crinetics Pharmaceuticals reports FDA approval for PALSONIFY in acromegaly, marking its transition to a commercial-stage company, alongside pipeline advancements and a strong capital position.

Crinetics Pharmaceuticals provides an update on its clinical-stage endocrine disease therapies, including the submission of a New Drug Application (NDA) to the FDA for paltusotine.

Crinetics Pharmaceuticals amends its lease agreement, files its annual report on Form 10-K, and updates its insider trading policy, outlining key business activities and financial safeguards.

Wendell Wierenga, a Director of Crinetics Pharmaceuticals, Inc., reported multiple transactions in common stock on September 1, 2026.

Coelho Rogerio Vivaldi, a Director of Crinetics Pharmaceuticals, Inc., reported multiple transactions in common stock on September 1, 2026.

Stephanie Okey, a Director of Crinetics Pharmaceuticals, Inc., reported multiple transactions in common stock on September 1, 2026.

Weston Nichols, a Director of Crinetics Pharmaceuticals, Inc., reported multiple transactions in common stock on September 1, 2026.

Matthew K Fust, a Director of Crinetics Pharmaceuticals, Inc., reported multiple transactions in common stock on September 1, 2026.

Caren Deardorf, a Director of Crinetics Pharmaceuticals, Inc., reported multiple transactions in common stock on September 1, 2026.

Crinetics Pharmaceuticals, Inc. has announced its 2026 Annual Meeting of Shareholders, scheduled for June 18, 2026, to elect directors, ratify auditor selection, and vote on executive compensation.

Crinetics Pharmaceuticals issues a supplement to its proxy statement to correct clerical errors regarding the day of the week for the annual meeting and the deadline for stockholder proposals.

Crinetics Pharmaceuticals will hold its annual stockholders meeting on June 11, 2025, to elect directors, ratify the selection of an independent accounting firm, and conduct an advisory vote on executive compensation.

Crinetics Pharmaceuticals sets June 11, 2025, for its annual stockholder meeting to elect directors, ratify the selection of an independent accounting firm, and conduct an advisory vote on executive compensation.

Crinetics Pharmaceuticals will hold its annual stockholders meeting on June 7, 2024, to vote on director elections, auditor ratification, executive compensation, and other business.

Crinetics Pharmaceuticals will hold its annual meeting of stockholders virtually on June 7, 2024, to vote on director elections, auditor ratification, and executive compensation.

Wellington Management Group LLP and its affiliates have filed a Schedule 13G, reporting beneficial ownership of 7,131,084 shares, representing approximately 6.8% of Crinetics Pharmaceuticals, Inc.'s common stock as of June 30, 2026.

FMR LLC and Abigail P. Johnson have updated their Schedule 13G filing, reporting a combined beneficial ownership of 1.4% in Crinetics Pharmaceuticals Inc. common stock as of July 31, 2026.

Farallon Capital Management, L.L.C. and associated entities have reported beneficial ownership of 8.5% of Crinetics Pharmaceuticals, Inc. common stock as of June 30, 2026.

Wellington Management Group LLP and its affiliates have reported beneficial ownership of 7.8% of Crinetics Pharmaceuticals, Inc. common stock as of March 31, 2026.

Driehaus Capital Management LLC has filed an amendment to its Schedule 13G, reporting a decrease in its beneficial ownership of Crinetics Pharmaceuticals, Inc. common stock to 6.11% as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.19% of Crinetics Pharmaceuticals Inc.'s common stock as of March 31, 2026.